Cargando…
Transparency, Power, and Influence in the Pharmaceutical Industry : Policy Gain or Confidence Game? /
There is plenty of controversy surrounding pharmaceuticals, but it cannot be denied that it is both a socially beneficial and profit-making industry. Regulators are expected to ensure that the economic success of the pharmaceutical industry does not come at the expense of public safety, yet regulato...
| Clasificación: | Libro Electrónico |
|---|---|
| Otros Autores: | , , , , , , , , , , , , |
| Formato: | Electrónico eBook |
| Idioma: | Inglés |
| Publicado: |
Toronto :
University of Toronto Press,
[2021]
|
| Temas: | |
| Acceso en línea: | Texto completo Texto completo |
MARC
| LEADER | 00000nam a22000005i 4500 | ||
|---|---|---|---|
| 001 | DEGRUYTERUP_9781487529055 | ||
| 003 | DE-B1597 | ||
| 005 | 20221201113901.0 | ||
| 006 | m|||||o||d|||||||| | ||
| 007 | cr || |||||||| | ||
| 008 | 221201t20212021onc fo d z eng d | ||
| 010 | |a 2021275609 | ||
| 020 | |a 9781487529055 | ||
| 024 | 7 | |a 10.3138/9781487529055 |2 doi | |
| 035 | |a (DE-B1597)596745 | ||
| 035 | |a (OCoLC)1240721288 | ||
| 040 | |a DE-B1597 |b eng |c DE-B1597 |e rda | ||
| 041 | 0 | |a eng | |
| 044 | |a onc |c CA-ON | ||
| 050 | 0 | 0 | |a RA401.A1 |b T73 2021 |
| 072 | 7 | |a MED000000 |2 bisacsh | |
| 245 | 0 | 0 | |a Transparency, Power, and Influence in the Pharmaceutical Industry : |b Policy Gain or Confidence Game? / |c ed. by Katherine Fierlbeck, Janice Graham, Matthew Herder. |
| 264 | 1 | |a Toronto : |b University of Toronto Press, |c [2021] | |
| 264 | 4 | |c ©2021 | |
| 300 | |a 1 online resource (304 p.) : |b 1 figure | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 347 | |a text file |b PDF |2 rda | ||
| 505 | 0 | 0 | |t Frontmatter -- |t Contents -- |t 1 Introduction -- |t 2 Transparency, Pharmaceuticals, and the Problem of Policy Change -- |t 3 Data Transparency and Pharmaceutical Regulation in Europe: Road to Damascus, or Room without a View? -- |t 4 The FDA and Health Canada: Similar Origins, yet Divergent Paths and Approaches to Transparency -- |t 5 Clinical Trial Data Transparency in Canada: Mapping the Progress from Laggard to Leader -- |t 6 The Limits of Transparency and the Role of Essential Medicines -- |t 7 Speak No Secrets: (Non)transparency in Health Canada's Communications about Pharmaceutical Regulation -- |t 8 The Political Economy of Influence: Ghost-Management in the Pharmaceutical Sector -- |t 9 Data Transparency and Rare Disease: Privacy versus Public Interest? -- |t 10 The European Registration of the Pandemic Influenza Vaccine Pandemrix: A Case Study of the Consequences of Poor Clinical Data Transparency -- |t 11 The Road Forward: How Researchers Can Sustain an Ethical and Transparent Health System -- |t 12 Conclusion -- |t Contributors -- |t Index |
| 506 | 0 | |a restricted access |u http://purl.org/coar/access_right/c_16ec |f online access with authorization |2 star | |
| 520 | |a There is plenty of controversy surrounding pharmaceuticals, but it cannot be denied that it is both a socially beneficial and profit-making industry. Regulators are expected to ensure that the economic success of the pharmaceutical industry does not come at the expense of public safety, yet regulators have also assumed a cooperative role by providing advice on regulation and by targeting unmet medical needs. Concerns over regulatory standards, conflicts of interest, and the manipulation of information on drug safety and effectiveness have led to public mistrust and a greater need for transparency between pharmaceutical industry and government regulators. Transparency, Power, and Influence in the Pharmaceutical Industry evaluates the progress made in holding the pharmaceutical industry responsible for creating transparency in the industry, from development to market. The contributors to this volume examine the various mechanisms introduced to make the regulatory process more informative and situate these efforts within the larger project of enhancing the safety of drugs, vaccines, and other products. | ||
| 538 | |a Mode of access: Internet via World Wide Web. | ||
| 546 | |a In English. | ||
| 588 | 0 | |a Description based on online resource; title from PDF title page (publisher's Web site, viewed 01. Dez 2022) | |
| 650 | 0 | |a Pharmaceutical policy |z Canada. | |
| 650 | 0 | |a Pharmaceutical policy |z European Union countries. | |
| 650 | 0 | |a Pharmaceutical policy |z United States. | |
| 650 | 7 | |a MEDICAL / General. |2 bisacsh | |
| 653 | |a clinical data. | ||
| 653 | |a conflicts of interest. | ||
| 653 | |a drugs. | ||
| 653 | |a ema. | ||
| 653 | |a fda. | ||
| 653 | |a health Canada. | ||
| 653 | |a health law. | ||
| 653 | |a health policy. | ||
| 653 | |a pharmaceutical regulation. | ||
| 653 | |a pharmaceuticals. | ||
| 653 | |a power. | ||
| 653 | |a scientific evidence. | ||
| 653 | |a transparency. | ||
| 700 | 1 | |a Banzi, Rita, |e contributor. |4 ctb |4 https://id.loc.gov/vocabulary/relators/ctb | |
| 700 | 1 | |a Danyliuk, Anna, |e contributor. |4 ctb |4 https://id.loc.gov/vocabulary/relators/ctb | |
| 700 | 1 | |a Davis, Courtney, |e contributor. |4 ctb |4 https://id.loc.gov/vocabulary/relators/ctb | |
| 700 | 1 | |a Fierlbeck, Katherine, |e contributor. |4 ctb |4 https://id.loc.gov/vocabulary/relators/ctb | |
| 700 | 1 | |a Fierlbeck, Katherine, |e editor. |4 edt |4 http://id.loc.gov/vocabulary/relators/edt | |
| 700 | 1 | |a Gagnon, Marc-André, |e contributor. |4 ctb |4 https://id.loc.gov/vocabulary/relators/ctb | |
| 700 | 1 | |a Ghimire, Kanksha Mahadevia, |e contributor. |4 ctb |4 https://id.loc.gov/vocabulary/relators/ctb | |
| 700 | 1 | |a Graham, Janice, |e contributor. |4 ctb |4 https://id.loc.gov/vocabulary/relators/ctb | |
| 700 | 1 | |a Graham, Janice, |e editor. |4 edt |4 http://id.loc.gov/vocabulary/relators/edt | |
| 700 | 1 | |a Herder, Matthew, |e contributor. |4 ctb |4 https://id.loc.gov/vocabulary/relators/ctb | |
| 700 | 1 | |a Herder, Matthew, |e editor. |4 edt |4 http://id.loc.gov/vocabulary/relators/edt | |
| 700 | 1 | |a Jefferson, Tom, |e contributor. |4 ctb |4 https://id.loc.gov/vocabulary/relators/ctb | |
| 700 | 1 | |a Lemmens, Trudo, |e contributor. |4 ctb |4 https://id.loc.gov/vocabulary/relators/ctb | |
| 700 | 1 | |a Lexchin, Joel, |e contributor. |4 ctb |4 https://id.loc.gov/vocabulary/relators/ctb | |
| 700 | 1 | |a Mulinari, Shai, |e contributor. |4 ctb |4 https://id.loc.gov/vocabulary/relators/ctb | |
| 700 | 1 | |a Persaud, Nav, |e contributor. |4 ctb |4 https://id.loc.gov/vocabulary/relators/ctb | |
| 773 | 0 | 8 | |i Title is part of eBook package: |d De Gruyter |t University of Toronto Press Complete eBook-Package 2021 |z 9783110739220 |
| 776 | 0 | |c print |z 9781487529031 | |
| 856 | 4 | 0 | |u https://doi.uam.elogim.com/10.3138/9781487529055 |z Texto completo |
| 856 | 4 | 0 | |u https://degruyter.uam.elogim.com/isbn/9781487529055 |z Texto completo |
| 912 | |a 978-3-11-073922-0 University of Toronto Press Complete eBook-Package 2021 |b 2021 | ||
| 912 | |a GBV-deGruyter-alles | ||